Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

Supplementary Data S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML

<p>Raw RNAseq data corresponding to Figures 2C, 4D and Supplemental Figure 2B</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Christopher T. Letson (16424095) (author)
Rannpháirtithe:	Maria E. Balasis (15033630) (author), Hannah Newman (15033618) (author), Moritz Binder (16424098) (author), Alexis Vedder (16424101) (author), Fumi Kinose (16424104) (author), Markus Ball (15033633) (author), Traci Kruer (15134201) (author), Ariel Quintana (16424107) (author), Terra L. Lasho (16424110) (author), Christy M. Finke (16424113) (author), Luciana L. Almada (16424116) (author), Jennifer M. Grants (16424119) (author), Guolin Zhang (15098544) (author), Martin E. Fernandez-Zapico (16424122) (author), Alexandre Gaspar-Maia (16424125) (author), Jeffrey Lancet (16424128) (author), Rami Komrokji (16424131) (author), Eric Haura (16424134) (author), David A. Sallman (15134216) (author), Gary W. Reuther (16424137) (author), Aly Karsan (15024852) (author), Uwe Rix (15040221) (author), Mrinal M. Patnaik (16424140) (author), Eric Padron (15134222) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Cell Signaling Growth factors Gene Regulation Posttranscriptional and translational control Hematological Cancers Leukemias Translational Research
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Supplementary Data S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
de réir: Christopher T. Letson (16424095)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
de réir: Christopher T. Letson (16424095)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
de réir: Christopher T. Letson (16424095)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML
de réir: Christopher T. Letson (16424095)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
de réir: Jonathan M.J. Derry (16648337)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
de réir: Jonathan M.J. Derry (16648337)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
de réir: Jonathan M.J. Derry (16648337)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
de réir: Jonathan M.J. Derry (16648337)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S5 from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
de réir: Jonathan M.J. Derry (16648337)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S6A from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
de réir: Jonathan M.J. Derry (16648337)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S6B from Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
de réir: Jonathan M.J. Derry (16648337)
Foilsithe / Cruthaithe: (2025)

Table S1 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
de réir: Yun-Guang Hong (14960966)
Foilsithe / Cruthaithe: (2025)

Table S2 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
de réir: Yun-Guang Hong (14960966)
Foilsithe / Cruthaithe: (2025)

Table S3 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
de réir: Yun-Guang Hong (14960966)
Foilsithe / Cruthaithe: (2025)

Table S4 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
de réir: Yun-Guang Hong (14960966)
Foilsithe / Cruthaithe: (2025)

Table S5 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
de réir: Yun-Guang Hong (14960966)
Foilsithe / Cruthaithe: (2025)

Table S6 from The RNA m<sup>6</sup>A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression
de réir: Yun-Guang Hong (14960966)
Foilsithe / Cruthaithe: (2025)

Figure 1 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
de réir: Meng Li (79487)
Foilsithe / Cruthaithe: (2025)

Figure 2 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
de réir: Meng Li (79487)
Foilsithe / Cruthaithe: (2025)

Figure 3 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
de réir: Meng Li (79487)
Foilsithe / Cruthaithe: (2025)

Figure 4 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
de réir: Meng Li (79487)
Foilsithe / Cruthaithe: (2025)

Figure 5 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
de réir: Meng Li (79487)
Foilsithe / Cruthaithe: (2025)

Figure 6 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
de réir: Meng Li (79487)
Foilsithe / Cruthaithe: (2025)

Figure 7 from Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival
de réir: Meng Li (79487)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma
de réir: Shima Nakanishi (16336496)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from The Polyamine–Hypusine Circuit Controls an Oncogenic Translational Program Essential for Malignant Conversion in MYC-Driven Lymphoma
de réir: Shima Nakanishi (16336496)
Foilsithe / Cruthaithe: (2025)

Supplementary Tables S1-5 from METTL3-Mediated m<sup>6</sup>A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
de réir: Yiming Wu (15306005)
Foilsithe / Cruthaithe: (2025)

Table S1 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
de réir: Xun-Xi Lu (14952883)
Foilsithe / Cruthaithe: (2025)

Table S2 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
de réir: Xun-Xi Lu (14952883)
Foilsithe / Cruthaithe: (2025)

Table S3 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
de réir: Xun-Xi Lu (14952883)
Foilsithe / Cruthaithe: (2025)

Table S7 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
de réir: Xun-Xi Lu (14952883)
Foilsithe / Cruthaithe: (2025)

Table S8 from An <i>In Vivo</i> CRISPR Screen Identifies That SNRPC Promotes Triple-Negative Breast Cancer Progression
de réir: Xun-Xi Lu (14952883)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 1 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
de réir: Duygu Kuzuoglu-Ozturk (14960213)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 2 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
de réir: Duygu Kuzuoglu-Ozturk (14960213)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 3 from N-myc–Mediated Translation Control Is a Therapeutic Vulnerability in Medulloblastoma
de réir: Duygu Kuzuoglu-Ozturk (14960213)
Foilsithe / Cruthaithe: (2025)

Table S2 from MEX3A Mediates p53 Degradation to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis
de réir: Cheng-Kai Wang (14963880)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
de réir: Yufang Bao (15386826)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
de réir: Yufang Bao (15386826)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
de réir: Yufang Bao (15386826)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
de réir: Yufang Bao (15386826)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_2s6gdphv9su9ogbkj310u02m27